News & Events


ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia
07.19.23
Join ARMGO at BIO International Convention, Boston, USA, June 05 – 08, 2023
05.05.23
Join ARMGO at 19th Orphan Drugs & Rare Disease Global Congress 2023, London, UK, April 3 – 4, 2023
03.31.23
Join ARMGO at Rare Disease Innovation & Partnership Summit in Philadelphia, USA, March 21 – 23, 2023
03.21.23
Join ARMGO at BIO-EUROPE in Leipzig, Germany, October 24 – 26, 2022
10.14.22
ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases
12.20.21
ARMGO Pharma Inc. Announces Clinical Trial of ARM210/S48168 for the Treatment of Ryanodine Receptor Type 1 Related Myopathies
12.17.19
ARMGO Pharma Receives FDA Orphan Drug Designation for ARM210/S48168 for the Treatment of Ryanodine Receptor Type 1 Related Myopathies
09.05.18